

IMMUNOMEDICS INC

Form 4

January 11, 2011

**FORM 4**
**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**GOLDENBERG DAVID M**

(Last) (First) (Middle)

**C/O IMMUNOMEDICS, INC., 300  
AMERICAN ROAD**

(Street)

**MORRIS PLAINS, NJ 07950**

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol

**IMMUNOMEDICS INC [IMMU]**

3. Date of Earliest Transaction  
(Month/Day/Year)

**01/05/2011**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☒ 10% Owner  
☒ Officer (give title below) ☐ Other (specify  
below)

CSO, CMO & Chairman of the BOD

6. Individual or Joint/Group Filing(Check  
Applicable Line)

☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount (A) or (D)	Price	
Common Stock <sup>(1)</sup>	01/05/2011		G		7,471	D \$ 0	3,782,527 D
Common Stock <sup>(1)</sup>	01/05/2011		G		7,471	D \$ 0	3,775,056 D
Common Stock <sup>(1)</sup>	01/05/2011		G		7,471	D \$ 0	3,767,585 D
Common Stock <sup>(1)</sup>	01/05/2011		G		7,471	D \$ 0	3,760,114 D
Common Stock <sup>(1)</sup>	01/05/2011		G		7,471	D \$ 0	3,752,643 D

Edgar Filing: IMMUNOMEDICS INC - Form 4

Common Stock <u>(1)</u>	01/05/2011	G	7,471	D	\$ 0	3,745,172	D	
Common Stock <u>(1)</u>	01/05/2011	G	7,471	D	\$ 0	3,737,701	D	
Common Stock <u>(1)</u>	01/05/2011	G	7,471	D	\$ 0	3,730,230	D	
Common Stock <u>(1)</u>	01/05/2011	G	7,471	D	\$ 0	3,722,759	D	
Common Stock <u>(1)</u>	01/05/2011	G	7,471	D	\$ 0	3,715,288	D	
Common Stock <u>(1)</u>	01/05/2011	G	7,471	D	\$ 0	3,707,817	D	
Common Stock <u>(1)</u>	01/05/2011	G	7,471	D	\$ 0	3,700,346	D	
Common Stock <u>(1)</u>	01/05/2011	G	7,471	D	\$ 0	3,692,875	D	
Common Stock <u>(1)</u>	01/05/2011	G	7,471	D	\$ 0	3,685,404	D	
Common Stock <u>(1)</u>	01/05/2011	G	7,471	D	\$ 0	3,677,933	D	
Common Stock <u>(2)</u>						2,103,362	I	See footnote <u>(2)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Transaction (Instr. 6)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GOLDENBERG DAVID M C/O IMMUNOMEDICS, INC. 300 AMERICAN ROAD MORRIS PLAINS, NJ 07950	X	X	CSO, CMO & Chairman of the BOD	

## Signatures

/s/ David M.  
Goldenberg 01/11/2011

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person gifted these shares of common stock to his family members and certain trusts established for the benefit of his family members. The reporting person is not deemed to be the beneficial owner of these shares.
- (2) Such shares are held by the reporting person's wife (including a total of 190,000 shares held as joint tenants by the reporting person and his spouse), by various trusts established for the benefit of the reporting person and/or family members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is a director. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.